BioCentury | Mar 20, 2021
Emerging Company Profile

Blackfynn: optimizing trial design for neurodegenerative therapies

...University of RochesterCorporate partners: ClintrexNumber of employees: 30Funds raised: UndisclosedInvestors: UndisclosedCEO: Amanda BanksPatents: Undisclosed Danielle Golovin Blackfynn Inc. The Michael J. Fox Foundation For Parkinson's Research University...
BioCentury | Dec 5, 2020
Translation in Brief

James Wilson developing gene therapy version of Regeneron COVID mAb cocktail; plus an oncolytic adenovirus, MapLight-Michael J. Fox Foundation and more

...of Medicine Case Western Reserve University Stanford University University of Pennsylvania Regeneron Pharmaceuticals Inc. Multiple Myeloma Research Foundation (MMRF) Dana-Farber Cancer Institute The Michael J. Fox Foundation For Parkinson's Research Phospholipase...
BioCentury | Jun 20, 2019
Emerging Company Profile

Casma: Tailoring autophagy targets to indications

...the compounds in cell-based and animal studies. In May, Casma received a $370,000 grant from the Michael J. Fox Foundation For Parkinson's Research...
...Ventures CEO: Keith Dionne Patents: None Companies and Institutions Mentioned Casma Therapeutics Inc., Cambridge, Mass. Michael J. Fox Foundation For Parkinson's Research...
BioCentury | May 10, 2019
Product Development

The time is now: novel partnerships and funding models for accelerating science to the marketplace

...Impact Investing Network (GIIN), New York, N.Y. The Leukemia & Lymphoma Society, White Plains, N.Y. The Michael J. Fox Foundation for Parkinson's Research...
BioCentury | Feb 28, 2019
Tools & Techniques

Synuclein PET project

...FTDP-17) - Microtubule-associated protein τ Allison Johnson, Staff Writer AC Immune S.A. Aprinoia Therapeutics Inc. Biogen Inc. Eli Lilly and Co. The Michael J. Fox Foundation For Parkinson's Research University...
BioCentury | Jan 31, 2018
Politics & Policy

AMP expands into Parkinson's

...five-year, $24 million expansion into Parkinson's disease that builds on a biomarker study run by the Michael J. Fox Foundation For Parkinson's Research...
... Mark Zipkin Foundation for the National Institutes of Health GlaxoSmithKline plc National Institutes of Health Pfizer Inc. Sanofi Verily Life Sciences LLC The Michael J. Fox Foundation For Parkinson's Research Celgene...
BioCentury | Aug 16, 2017
Clinical News

AZ's Bydureon improves motor function in Phase II for PD

...point vs. a decline of 2.1 points, p=0.0318). The double-blind, U.K. trial was funded by The Michael J. Fox Foundation For Parkinson's Research...
...the off-medication state at week 60 Status: Phase II data Milestone: NA Jaime De Leon Bydureon Exenatide once weekly The Michael J. Fox Foundation For Parkinson's Research University...
BioCentury | Apr 7, 2017
Strategy

Pushing for progress in Prader-Willi

...Staff Writer Aix-Marseille University Cardiff University Cystic Fibrosis Foundation Foundation for Prader-Willi Research Italian Institute of Technology Multiple Myeloma Research Foundation (MMRF) The Michael J. Fox Foundation For Parkinson's Research University...
BioCentury | Jan 19, 2017
Finance

IMI branches out

...Writer AITbiotech Pte. Ltd. Atreca Inc. Autism Speaks Inc. Beijing Novogene Bioinformatics Technology Co. Ltd. General Electric Co. Innovative Medicines Initiative (IMI) JDRF The Michael J. Fox Foundation For Parkinson's Research University...
BioCentury | Oct 17, 2016
Politics, Policy & Law

Pruning REGROW

...groups and pharmaceutical companies. In May, 10 patient groups, including the Cystic Fibrosis Foundation and the Michael J. Fox Foundation for Parkinson's Research...
...Francisco, Calif. Cystic Fibrosis Foundation, Bethesda, Md. International Society for Stem Cell Research, Skokie, Ill. The Michael J. Fox Foundation for Parkinson's Research...
Items per page:
1 - 10 of 84
BioCentury | Mar 20, 2021
Emerging Company Profile

Blackfynn: optimizing trial design for neurodegenerative therapies

...University of RochesterCorporate partners: ClintrexNumber of employees: 30Funds raised: UndisclosedInvestors: UndisclosedCEO: Amanda BanksPatents: Undisclosed Danielle Golovin Blackfynn Inc. The Michael J. Fox Foundation For Parkinson's Research University...
BioCentury | Dec 5, 2020
Translation in Brief

James Wilson developing gene therapy version of Regeneron COVID mAb cocktail; plus an oncolytic adenovirus, MapLight-Michael J. Fox Foundation and more

...of Medicine Case Western Reserve University Stanford University University of Pennsylvania Regeneron Pharmaceuticals Inc. Multiple Myeloma Research Foundation (MMRF) Dana-Farber Cancer Institute The Michael J. Fox Foundation For Parkinson's Research Phospholipase...
BioCentury | Jun 20, 2019
Emerging Company Profile

Casma: Tailoring autophagy targets to indications

...the compounds in cell-based and animal studies. In May, Casma received a $370,000 grant from the Michael J. Fox Foundation For Parkinson's Research...
...Ventures CEO: Keith Dionne Patents: None Companies and Institutions Mentioned Casma Therapeutics Inc., Cambridge, Mass. Michael J. Fox Foundation For Parkinson's Research...
BioCentury | May 10, 2019
Product Development

The time is now: novel partnerships and funding models for accelerating science to the marketplace

...Impact Investing Network (GIIN), New York, N.Y. The Leukemia & Lymphoma Society, White Plains, N.Y. The Michael J. Fox Foundation for Parkinson's Research...
BioCentury | Feb 28, 2019
Tools & Techniques

Synuclein PET project

...FTDP-17) - Microtubule-associated protein τ Allison Johnson, Staff Writer AC Immune S.A. Aprinoia Therapeutics Inc. Biogen Inc. Eli Lilly and Co. The Michael J. Fox Foundation For Parkinson's Research University...
BioCentury | Jan 31, 2018
Politics & Policy

AMP expands into Parkinson's

...five-year, $24 million expansion into Parkinson's disease that builds on a biomarker study run by the Michael J. Fox Foundation For Parkinson's Research...
... Mark Zipkin Foundation for the National Institutes of Health GlaxoSmithKline plc National Institutes of Health Pfizer Inc. Sanofi Verily Life Sciences LLC The Michael J. Fox Foundation For Parkinson's Research Celgene...
BioCentury | Aug 16, 2017
Clinical News

AZ's Bydureon improves motor function in Phase II for PD

...point vs. a decline of 2.1 points, p=0.0318). The double-blind, U.K. trial was funded by The Michael J. Fox Foundation For Parkinson's Research...
...the off-medication state at week 60 Status: Phase II data Milestone: NA Jaime De Leon Bydureon Exenatide once weekly The Michael J. Fox Foundation For Parkinson's Research University...
BioCentury | Apr 7, 2017
Strategy

Pushing for progress in Prader-Willi

...Staff Writer Aix-Marseille University Cardiff University Cystic Fibrosis Foundation Foundation for Prader-Willi Research Italian Institute of Technology Multiple Myeloma Research Foundation (MMRF) The Michael J. Fox Foundation For Parkinson's Research University...
BioCentury | Jan 19, 2017
Finance

IMI branches out

...Writer AITbiotech Pte. Ltd. Atreca Inc. Autism Speaks Inc. Beijing Novogene Bioinformatics Technology Co. Ltd. General Electric Co. Innovative Medicines Initiative (IMI) JDRF The Michael J. Fox Foundation For Parkinson's Research University...
BioCentury | Oct 17, 2016
Politics, Policy & Law

Pruning REGROW

...groups and pharmaceutical companies. In May, 10 patient groups, including the Cystic Fibrosis Foundation and the Michael J. Fox Foundation for Parkinson's Research...
...Francisco, Calif. Cystic Fibrosis Foundation, Bethesda, Md. International Society for Stem Cell Research, Skokie, Ill. The Michael J. Fox Foundation for Parkinson's Research...
Items per page:
1 - 10 of 84